AJP:MED15可能作为头颈部鳞癌复发标志物

2015-03-21 MedSci MedSci原创

一项新的研究为中介复杂单元15(MED15) 在头颈部鳞状细胞癌(HNSCC)发生发展中可能起到的至关重要作用提供了第一个病理生理学证据。这项发表在The American Journal of Pathology杂志上的研究结果,MED15过表达与复发的HNSCC患者的高死亡率相关,尤其是口腔/咽部肿瘤。而MED15过表达与酗酒这一HNSCC的危险因素有关。HNSCC是世界第六位最常见的癌症,其

一项新的基因标志物---MED15 在头颈部鳞状细胞癌(HNSCC)发生发展中可能起到的至关重要作用提供了第一个病理生理学证据。这项发表在The American Journal of Pathology杂志上的研究结果,MED15过表达与复发的HNSCC患者的高死亡率相关,尤其是口腔/咽部肿瘤。而MED15过表达与酗酒这一HNSCC的危险因素有关。

HNSCC是世界第六位最常见的癌症,其高复发率以及高早期转移率在每年导致约350000人死亡。德国波恩大学医院的耳鼻喉科学学系、病理学研究所首席研究员Sven Perner博士说:“我们的研究发现表明,MED15可能作为HNSCC复发标记并有希望成为复发性HNSCC治疗靶点。”

中介子是一个多蛋白复合体,具有调节多种信号通路的作用。在人类中,它由包括MED15的30亚单位组成,而MED15则已经在过去研究中被证实与乳腺癌和前列腺癌相关。MED15在介导转化生长因子β(TGF-β)的信号通路中发挥的重要作用已经引起研究者们的关注。Perner博士指出:“研究证据表明,多个信号通路的异常与HNSCC的进展相关,这就要求研究者们对参与在HNSCC进展的这些信号通路中的相关分子进行更深入的探讨。”

为了研究MED15在HNSCC中所扮演的角色,研究人员对113例原发肿瘤组织、30例复发性肿瘤组织、85例转移淋巴结以及20例正常鳞状上皮组织对照样本进行分析。通过免疫组织化学染色,计算表达分数并按照细胞的染色深度分为无表达(<0.07)、低表达(>0.07&<0.2)和过表达(>0.2)三组。他们发现MED15过表达出现在35%的原发性肿瘤、30%转移淋巴结和70%的复发肿瘤组织中,而在对照样本中则没有或者低表达。

为确定MED15的表达水平与死亡率的相关性,研究人员对108例复发性肿瘤组织进行了免疫组化分析。他们发现MED15过表达的肿瘤患者死亡率(定义为第一次诊断后1 - 12年内死亡)从58%上升到78%,提示MED15过表达与高死亡率之间具有显著的相关性。

进一步的研究显示,在口咽或口腔肿瘤患者的死亡率显著高于下咽部或喉肿瘤患者。同时,对比下咽部或喉肿瘤,口腔或口咽肿瘤组织中的MED15表达水平更高。研究还调查了MED15水平是否与任何HNSCC的风险因素相关,如吸烟、饮酒或慢性致瘤性人类乳头瘤病毒(HPV)感染。他们发现重度饮酒与MED15过表达显著相关,揭示了酒精不利影响的可能作用机制。

Perner博士和他的合作研究者们相信MED15可能是一种分子标记,可用于预测肿瘤复发或转移的风险,进而帮助临床医生做出早期诊断和治疗决策。研究结果发现, 74%的原发肿瘤样本和对应的淋巴结转移样本中检测出MED15过表达。此外,MED15表达水平与HNSCC组织的高增殖活性相关,并且基因水平上抑制MED15表达能够减弱细胞增殖和迁移能力。

Perner博士表示,MED15抑制剂可能是一个未来的治疗选择,特别是对于进展期以及复发的肿瘤患者。

原始出处:
Zaki Shaikhibrahim, Anne Offermann, Rebecca Halbach, Wenzel Vogel, Martin Braun, Glen Kristiansen, Friedrich Bootz, Jörg Wenzel, Ralf Mikut, Claudia Lengerke, Markus Reischl, Andreas Schröck, Sven Perner. Clinical and Molecular Implications of MED15 in Head and Neck Squamous Cell Carcinoma. The American Journal of Pathology, 2015; 185 (4): 1114 DOI:10.1016/j.ajpath.2014.12.010

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=125377, encodeId=396b1253e70b, content=好文章,还会关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Sep 13 14:32:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840833, encodeId=f321184083311, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Aug 25 19:54:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19887, encodeId=d6df1988e2c, content=关键是敏感性和特异性是多少?, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12781609448, createdName=wu2734033, createdTime=Tue Apr 07 18:39:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484616, encodeId=021414846168a, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491761, encodeId=386e1491e617b, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589684, encodeId=b9e71589684cc, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606441, encodeId=4ac81606441c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18660, encodeId=9afb1866076, content=MED15过表达出现在35%的原发性肿瘤、30%转移淋巴结和70%的复发肿瘤组织中,而在对照样本中则没有或者低表达。这一点仍然不够!还应该选择未转移的肿瘤进行队列观察,了解该基因高表达会不会转移更快或更早, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Mar 22 23:14:00 CST 2015, time=2015-03-22, status=1, ipAttribution=)]
    2016-09-13 1e10c84am36(暂无匿称)

    好文章,还会关注

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=125377, encodeId=396b1253e70b, content=好文章,还会关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Sep 13 14:32:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840833, encodeId=f321184083311, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Aug 25 19:54:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19887, encodeId=d6df1988e2c, content=关键是敏感性和特异性是多少?, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12781609448, createdName=wu2734033, createdTime=Tue Apr 07 18:39:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484616, encodeId=021414846168a, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491761, encodeId=386e1491e617b, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589684, encodeId=b9e71589684cc, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606441, encodeId=4ac81606441c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18660, encodeId=9afb1866076, content=MED15过表达出现在35%的原发性肿瘤、30%转移淋巴结和70%的复发肿瘤组织中,而在对照样本中则没有或者低表达。这一点仍然不够!还应该选择未转移的肿瘤进行队列观察,了解该基因高表达会不会转移更快或更早, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Mar 22 23:14:00 CST 2015, time=2015-03-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=125377, encodeId=396b1253e70b, content=好文章,还会关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Sep 13 14:32:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840833, encodeId=f321184083311, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Aug 25 19:54:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19887, encodeId=d6df1988e2c, content=关键是敏感性和特异性是多少?, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12781609448, createdName=wu2734033, createdTime=Tue Apr 07 18:39:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484616, encodeId=021414846168a, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491761, encodeId=386e1491e617b, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589684, encodeId=b9e71589684cc, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606441, encodeId=4ac81606441c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18660, encodeId=9afb1866076, content=MED15过表达出现在35%的原发性肿瘤、30%转移淋巴结和70%的复发肿瘤组织中,而在对照样本中则没有或者低表达。这一点仍然不够!还应该选择未转移的肿瘤进行队列观察,了解该基因高表达会不会转移更快或更早, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Mar 22 23:14:00 CST 2015, time=2015-03-22, status=1, ipAttribution=)]
    2015-04-07 wu2734033

    关键是敏感性和特异性是多少?

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=125377, encodeId=396b1253e70b, content=好文章,还会关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Sep 13 14:32:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840833, encodeId=f321184083311, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Aug 25 19:54:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19887, encodeId=d6df1988e2c, content=关键是敏感性和特异性是多少?, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12781609448, createdName=wu2734033, createdTime=Tue Apr 07 18:39:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484616, encodeId=021414846168a, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491761, encodeId=386e1491e617b, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589684, encodeId=b9e71589684cc, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606441, encodeId=4ac81606441c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18660, encodeId=9afb1866076, content=MED15过表达出现在35%的原发性肿瘤、30%转移淋巴结和70%的复发肿瘤组织中,而在对照样本中则没有或者低表达。这一点仍然不够!还应该选择未转移的肿瘤进行队列观察,了解该基因高表达会不会转移更快或更早, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Mar 22 23:14:00 CST 2015, time=2015-03-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=125377, encodeId=396b1253e70b, content=好文章,还会关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Sep 13 14:32:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840833, encodeId=f321184083311, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Aug 25 19:54:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19887, encodeId=d6df1988e2c, content=关键是敏感性和特异性是多少?, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12781609448, createdName=wu2734033, createdTime=Tue Apr 07 18:39:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484616, encodeId=021414846168a, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491761, encodeId=386e1491e617b, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589684, encodeId=b9e71589684cc, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606441, encodeId=4ac81606441c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18660, encodeId=9afb1866076, content=MED15过表达出现在35%的原发性肿瘤、30%转移淋巴结和70%的复发肿瘤组织中,而在对照样本中则没有或者低表达。这一点仍然不够!还应该选择未转移的肿瘤进行队列观察,了解该基因高表达会不会转移更快或更早, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Mar 22 23:14:00 CST 2015, time=2015-03-22, status=1, ipAttribution=)]
    2015-03-23 wshxjq
  6. [GetPortalCommentsPageByObjectIdResponse(id=125377, encodeId=396b1253e70b, content=好文章,还会关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Sep 13 14:32:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840833, encodeId=f321184083311, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Aug 25 19:54:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19887, encodeId=d6df1988e2c, content=关键是敏感性和特异性是多少?, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12781609448, createdName=wu2734033, createdTime=Tue Apr 07 18:39:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484616, encodeId=021414846168a, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491761, encodeId=386e1491e617b, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589684, encodeId=b9e71589684cc, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606441, encodeId=4ac81606441c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18660, encodeId=9afb1866076, content=MED15过表达出现在35%的原发性肿瘤、30%转移淋巴结和70%的复发肿瘤组织中,而在对照样本中则没有或者低表达。这一点仍然不够!还应该选择未转移的肿瘤进行队列观察,了解该基因高表达会不会转移更快或更早, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Mar 22 23:14:00 CST 2015, time=2015-03-22, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=125377, encodeId=396b1253e70b, content=好文章,还会关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Sep 13 14:32:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840833, encodeId=f321184083311, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Aug 25 19:54:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19887, encodeId=d6df1988e2c, content=关键是敏感性和特异性是多少?, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12781609448, createdName=wu2734033, createdTime=Tue Apr 07 18:39:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484616, encodeId=021414846168a, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491761, encodeId=386e1491e617b, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589684, encodeId=b9e71589684cc, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606441, encodeId=4ac81606441c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18660, encodeId=9afb1866076, content=MED15过表达出现在35%的原发性肿瘤、30%转移淋巴结和70%的复发肿瘤组织中,而在对照样本中则没有或者低表达。这一点仍然不够!还应该选择未转移的肿瘤进行队列观察,了解该基因高表达会不会转移更快或更早, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Mar 22 23:14:00 CST 2015, time=2015-03-22, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=125377, encodeId=396b1253e70b, content=好文章,还会关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Sep 13 14:32:00 CST 2016, time=2016-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840833, encodeId=f321184083311, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Aug 25 19:54:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19887, encodeId=d6df1988e2c, content=关键是敏感性和特异性是多少?, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12781609448, createdName=wu2734033, createdTime=Tue Apr 07 18:39:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484616, encodeId=021414846168a, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491761, encodeId=386e1491e617b, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589684, encodeId=b9e71589684cc, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606441, encodeId=4ac81606441c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Mar 23 13:54:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18660, encodeId=9afb1866076, content=MED15过表达出现在35%的原发性肿瘤、30%转移淋巴结和70%的复发肿瘤组织中,而在对照样本中则没有或者低表达。这一点仍然不够!还应该选择未转移的肿瘤进行队列观察,了解该基因高表达会不会转移更快或更早, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Mar 22 23:14:00 CST 2015, time=2015-03-22, status=1, ipAttribution=)]
    2015-03-22 lovetcm

    MED15过表达出现在35%的原发性肿瘤、30%转移淋巴结和70%的复发肿瘤组织中,而在对照样本中则没有或者低表达。这一点仍然不够!还应该选择未转移的肿瘤进行队列观察,了解该基因高表达会不会转移更快或更早

    0

相关资讯

Lancet Oncol:二期临床发现帕尼单抗不适用于晚期头颈部鳞癌

Panitumumab即帕尼单抗,是第一个完全人源化单克隆抗体,其靶向作用于表皮生长因子受体(EGFR)。最初被用于治疗化疗失败后转移性结直肠癌。2007年开始,来自西班牙的Jordi Giralt教授牵头在全世界多个中心进行了一项随机的、对照的、开放的2期临床试验,比较帕尼单抗联合放射治疗与常规放化疗在在治疗未经切除的局部晚期头颈部鳞癌的治疗效果。 在该研究中,研究人员从8个国家的22个机构招

Clin Cancer Res:他达拉非能增加头颈部鳞癌患者的肿瘤特性免疫

目的:明确磷酸二酯酶5(PDE5)能否通过阻断髓源性抑制细胞(MDSC)进而增加头颈部肿瘤患者的免疫功能。 试验设计:我们做了一个随机的、前瞻性的、双盲的、有安慰剂对照的II期临床试验,用以明确PDE5抑制剂对于头颈部鳞癌患者免疫功能的作用。 结果:他达拉非增加了患者的免疫反应。相对于对照组的1.1倍,他达拉非组使患者体内T细胞扩增了2.4倍(P=0.01)。同时他达拉非使患者体内的外周MDS